Frédérique Berger

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Florence Dalenc et al. · The Lancet Oncology · 2022 · 285 citations

Breast Oncology, Esr1 Mutation, Endocrine-related Cancer +10

Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer

Armelle Corpet, Leanne de Koning, Joern Toedling et al. · The EMBO Journal · 2010 · 180 citations · Full text

Tumor Biology, Breast Oncology, Oncology +11

Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

François‐Clément Bidard, William Jacot, Nicolas Kiavué et al. · JAMA Oncology · 2020 · 168 citations · Full text

The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma

Rocío Montes de, Zachary A. Gurard‐Levin, Frédérique Berger et al. · Molecular Oncology · 2014 · 86 citations · Full text

Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer

David Groheux, Elif Hindié, Sylvie Giacchetti et al. · European Journal of Cancer · 2014 · 73 citations

Breast Oncology, Neoadjuvant Chemotherapy, Oncologic Imaging +10